Biotech gainers: OHR Pharmaceutical (NASDAQ:OHRP), La Jolla Pharmaceutical Company (NASDAQ:LJPC), bluebird bio (NASDAQ:BLUE), Esperion Therapeutics (NASDAQ:ESPR)
OHR Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. OHR Pharmaceutical Inc (NASDAQ:OHRP) stock opened at $14.73 in last session, and closed at $17.73, while the day range of stock is $14.73 – $17.85. The stock showed a positive weekly performance of 25.30%.
Chardan Capital began coverage on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $32.00 target price on the stock. La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock opened at $9.03, in last session and closed at $9.76, by gaining 9.79%. The 52 week range of the stock is $2.75 – $12.00. Company’s market capitalization is $42.99 million.
bluebird bio Inc. (NASDAQ:BLUE) presented at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place Hotel, Boston, MA. bluebird bio Inc (NASDAQ:BLUE) stock advanced 7.68% and finished the last session at $25.95. The EPS of the stock remained 18.89. Company’s market capitalization is $617.10 million.
ETC-1002, a novel agent in development by Esperion Therapeutics, Inc (NASDAQ:ESPR) lowered LDL levels by nearly 43% in patients with type 2 diabetes and hypercholesterolemia, according to phase 2 study results. Esperion Therapeutics Inc (NASDAQ:ESPR) stock opened the session at $16.63, and closed the session at $17.40. The 52 week range of the stock remained $10.90 – $20.10 and the day range was $16.37 – $17.74.